Overview

Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

Status:
Recruiting
Trial end date:
2028-09-23
Target enrollment:
Participant gender:
Summary
Phase III randomized clinical trial evaluating the sequencing of anthracyclines and taxanes in neoadjuvant therapy for locally advanced HER2-negative breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Latin American Cooperative Oncology Group
Collaborator:
Brazilian Breast Cancer Study Group (GBECAM)
Treatments:
Cyclophosphamide
Docetaxel
Paclitaxel